Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
EM Lewiecki - Drug, Healthcare and Patient Safety, 2011 - Taylor & Francis
Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …
[PDF][PDF] Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
EM Lewiecki - Drug, Healthcare and Patient Safety, 2011 - pdfs.semanticscholar.org
Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis.
EM Lewiecki - Drug, Healthcare and Patient Safety, 2011 - europepmc.org
Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …
[引用][C] Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
EM Lewiecki - Drug, Healthcare and Patient Safety, 2011 - cir.nii.ac.jp
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
[HTML][HTML] Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
EM Lewiecki - Drug, Healthcare and Patient Safety, 2011 - ncbi.nlm.nih.gov
Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
EM Lewiecki - Drug, healthcare and patient safety, 2011 - pubmed.ncbi.nlm.nih.gov
Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
EM Lewiecki - Drug, Healthcare and Patient Safety, 2011 - search.proquest.com
Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
EM Lewiecki - Drug, Healthcare and Patient Safety, 2011 - dovepress.com
Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis.
EM Lewiecki - Drug, Healthcare and Patient Safety, 2011 - europepmc.org
Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …